Overview

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

Status:
Not yet recruiting
Trial end date:
2022-01-24
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca